Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Nov 1;182(5):1213-21.
doi: 10.1084/jem.182.5.1213.

Infection of human endothelial cells with Epstein-Barr virus

Affiliations

Infection of human endothelial cells with Epstein-Barr virus

K Jones et al. J Exp Med. .

Abstract

Interleukin-6 (IL-6) promotes growth and tumorigenicity of Epstein-Barr virus (EBV)-immortalized B cells, and is abnormally elevated in the serum of solid organ transplant recipients who develop EBV-positive posttransplant lymphoproliferative disease (PTLD), but not in control transplant recipients. Endothelial cells derived from PTLD lesions were found to secrete spontaneously high levels of IL-6 in vitro for up to 4 mo. We examined possible mechanisms for sustained IL-6 production by endothelial cells. Here, we show that EBV can infect endothelial cells in vitro. After 3-4 wk incubation with lethally irradiated EBV-positive, but not EBV-negative cell lines, a proportion of human umbilical cord-derived endothelial cells (HUVECs) expressed in situ the EBV-encoded small RNAs (EBER). Southern blot analysis after polymerase chain reaction showed EBV DNA in HUVEC that had been incubated with lethally irradiated EBV-positive cells, but not in the controls. Exposure of HUVECs to lethally irradiated EBV-positive but not EBV-negative cell lines induced IL-6 production that was sustained for up to 120 d of culture. These studies identify endothelial cells as targets for EBV infection and raise the possibility that this infection may be important in the life cycle and pathology of EBV.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 1984 Jun;73(6):1789-95 - PubMed
    1. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5397-401 - PubMed
    1. Science. 1988 Jan 29;239(4839):502-4 - PubMed
    1. J Immunol. 1989 Jan 1;142(1):144-7 - PubMed
    1. J Exp Med. 1990 Jan 1;171(1):345-9 - PubMed

MeSH terms